These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25745188)

  • 1. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients.
    Lau WW; Hannah R; Green AR; Göttgens B
    Blood; 2015 Mar; 125(10):1679-81. PubMed ID: 25745188
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
    Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
    Rattarittamrong E; Tantiworawit A; Kumpunya N; Wongtagan O; Tongphung R; Phusua A; Chai-Adisaksopha C; Hantrakool S; Rattanathammethee T; Norasetthada L; Charoenkwan P; Lekawanvijit S
    Hematology; 2018 Oct; 23(9):613-619. PubMed ID: 29521158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.
    Monte-Mor Bda C; Ayres-Silva Jde P; Correia WD; Coelho AC; Solza C; Daumas AH; Bonamino MH; Santos FP; Datoguia TS; Pereira Wde O; Lisboa BC; Ramos CF; Machado-Neto JA; Hamerschlak N; Campregher PV; Traina F; Pagnano KB; Zalcberg I
    Blood Cells Mol Dis; 2016 Sep; 60():74-7. PubMed ID: 26994960
    [No Abstract]   [Full Text] [Related]  

  • 6. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.
    Fu R; Liu D; Cao Z; Zhu S; Li H; Su H; Zhang L; Xue F; Liu X; Zhang X; Cheng T; Yang R; Zhang L
    Leukemia; 2016 Mar; 30(3):746-9. PubMed ID: 26118316
    [No Abstract]   [Full Text] [Related]  

  • 7. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.
    Bonifacio M; Montemezzi R; Parisi A; De Matteis G; Bertorelle R; Scaffidi L; Candiotto C; Lippi G; Zamò A; Chilosi M; Pizzolo G; Scarpa A; Krampera M
    Ann Hematol; 2019 Oct; 98(10):2339-2346. PubMed ID: 31250082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
    Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
    Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
    Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
    J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
    Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
    Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
    Yang Y; Wang X; Wang C; Qin Y
    Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
    Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
    Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
    Sun C; Zhou X; Zou ZJ; Guo HF; Li JY; Qiao C
    Chin Med J (Engl); 2016 Aug; 129(15):1778-83. PubMed ID: 27453224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
    Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.
    Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L
    Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
    Tefferi A; Wassie EA; Guglielmelli P; Gangat N; Belachew AA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Pacilli A; Vannucchi AM; Passamonti F
    Am J Hematol; 2014 Aug; 89(8):E121-4. PubMed ID: 24753125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
    Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
    Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.